Clinical Trial Update: Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating LAS41003 for inflammatory tinea pedis has completed, reporting efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tinea Pedis

Drugs mentioned

• LAS41003

Snippet

Sponsor: Almirall, S.A. | Conditions: Tinea Pedis | Phase 2 | Status: COMPLETED